Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Leases (2019 - 2025)

Historic Operating Leases for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Q4 2025 value amounting to $109.7 million.

  • Arrowhead Pharmaceuticals' Operating Leases fell 534.97% to $109.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $109.7 million, marking a year-over-year decrease of 534.97%. This contributed to the annual value of $104.1 million for FY2025, which is 622.82% down from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Operating Leases stood at $109.7 million, which was down 534.97% from $104.1 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Operating Leases ranged from a high of $118.9 million in Q1 2024 and a low of $22.5 million during Q4 2021
  • In the last 5 years, Arrowhead Pharmaceuticals' Operating Leases had a median value of $93.4 million in 2023 and averaged $82.5 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Operating Leases soared by 26521.86% in 2022, and later tumbled by 622.82% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Operating Leases stood at $22.5 million in 2021, then surged by 265.22% to $82.1 million in 2022, then soared by 44.37% to $118.6 million in 2023, then decreased by 2.3% to $115.9 million in 2024, then dropped by 5.35% to $109.7 million in 2025.
  • Its Operating Leases stands at $109.7 million for Q4 2025, versus $104.1 million for Q3 2025 and $112.7 million for Q2 2025.